Navigation Links
Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
Date:9/27/2011

SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction.  

"We are very pleased to participate in the annual meeting of the American Society for Reproductive Medicine," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "Endometriosis is a leading cause of infertility in women and this scientific meeting brings together the world's thought leaders in obstetrics, gynecology, and endocrinology to discuss the latest advances in the field. We look forward to sharing our elagolix clinical data at this meeting."

An abstract from the Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will be presented at the 67th Annual Meeting of the American Society for Reproductive Medicine on Tuesday, October 18, 2011 at 4:15 pm during the abstract sessions. Bruce Carr, M.D. the Paul C. MacDonald Distinguished Chair in Obstetrics and Gynecology at University of Texas Southwestern Medical School will present "A Novel Oral GnRH Antagonist, Elagolix, is Effective For Reducing Endometriosis-Associated Pelvic Pain: Results of a 24-Week Randomized Study."

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and report on Form 10-Q for the quarter ended June 30, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
3. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
5. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
6. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
7. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
8. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
9. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
10. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
(Date:12/2/2016)... -- Around the corners of world, cancer has infused ... present over earth. Cancer has become one of those ... time this is because of the increasing incidence rates ... steady increase in global cancer incidence with its associated ... of treatment, there is increasing interest in this stringent ...
(Date:12/2/2016)... 2, 2016 bioLytical Laboratories (das "Unternehmen"), ein Weltführer ... seinen  INSTI HIV-Selbsttests  in einer Version mit geringeren Kosten einzuführen.  ... ... New: INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) ...
Breaking Medicine Technology:
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... ... 2016 , ... The annual time frame to change Medicare health and prescription ... December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan ... to make changes during this period order for their new policy to go into ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet ... in USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition ... lives. “We are prolonging life 6 years in the last 3 decades,” says ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
Breaking Medicine News(10 mins):